- Conditions
- High Risk Acute Myeloid Leukemia
- Interventions
- CPX-351, 7+3 (cytarabine and daunorubicin)
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone, Quality-of-Life Assessment, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
- Drug
- Lead sponsor
- Larysa Sanchez
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma, Large-Cell, Diffuse
- Interventions
- Rituximab, Etoposide, Carboplatine, Ifosfamide + Mesna, Cisplatine, Cytosine Arabinoside, Dexamethasone, Autologous Stem Cell Transplantation, BCNU, Cytarabine, Melphalan
- Drug · Procedure
- Lead sponsor
- Lymphoma Study Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 481 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, carboplatin, pemetrexed disodium
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 217
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 140 more
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Interventions
- Adjuvant hypofractionation, Definitive Hypofractionation
- Radiation
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 4
- States / cities
- New York, New York
- Conditions
- Leukemia, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- DT388IL3
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Acute Leukemias
- Interventions
- LDE225
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Lymphoma Cancer, Gynecological Cancers
- Interventions
- group intervention and questionnaires, individual phone intervention and questionnaires, expressive writing (arm will not be include in the randomization)
- Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Interventions
- Comprehensive Geriatric Assessment
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- tipifarnib, etoposide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 70 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- imatinib mesylate, paclitaxel
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 2
- States / cities
- Albuquerque, New Mexico • Seattle, Washington
- Conditions
- Lung Cancer
- Interventions
- erlotinib hydrochloride, gemcitabine hydrochloride
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 70 Years to 120 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Savannah, Georgia • Evanston, Illinois + 8 more
- Conditions
- Cancer
- Interventions
- GA-driven Intervention
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 3
- States / cities
- Rochester, New York
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CDOP plus rituximab
- Drug
- Lead sponsor
- Geriatric Oncology Consortium
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 5
- States / cities
- Oxnard, California • Washington D.C., District of Columbia • Inverness, Florida + 2 more
- Conditions
- Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
- Interventions
- Nanvuranlat, Physician's Best Choice
- Drug · Other
- Lead sponsor
- J-Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Duarte, California • Orange, California • Santa Monica, California + 15 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- combination therapy using decitabine and midostaurin
- Drug
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Sapacitabine, Arm A, Sapacitabine, Arm B, Sapacitabine, Arm C, Sapacitabine, Arm D, sapacitabine, Arm E, sapacitabine, Arm F, Sapacitabine, Arm G, Sapacitabine, Arm H, Sapacitabine, Arm I
- Drug
- Lead sponsor
- Cyclacel Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 10 more
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, docetaxel
- Biological · Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 75 Years to 120 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- granisetron transdermal system, Granisetron IV
- Drug
- Lead sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Other Cancer
- Interventions
- Clinician Communication Skills Training, Advance Care Planning (ACP) Decisions Videos Decisions Aids, Video Declarations (ViDec)
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 13,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • New Hyde Park, New York + 1 more
- Conditions
- Cancer, Rectal
- Interventions
- Short course radiation therapy
- Radiation
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Colorectal Cancer
- Interventions
- leucovorin calcium, tegafur-uracil
- Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 75 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 49
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more
- Conditions
- Bladder Cancer
- Interventions
- Educational Video Modules on Risk Prevention Before and After Cystectomy (Surgery), Geriatric Service/ Discharge Planning, Questionnaires
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois